D05.12
Intraductal carcinoma in situ of left breast
Clinical Classification Guidelines
Medical Intelligence & Overview
Intraductal carcinoma in situ of the left breast is a condition characterized by abnormal cell growth confined within the milk ducts. As a non-invasive entity, it usually does not cause symptoms and is frequently found during routine screening. The diagnosis hinges on imaging studies and biopsy confirmation. While DCIS itself is not life-threatening, it is considered a significant marker for increased breast cancer risk. Treatment focuses on removing the abnormal cells and preventing progression to invasive cancer, often through surgical and radiological interventions. Regular follow-up and screening are essential components of ongoing management.
Causes & Symptoms
Clinical Causes: Genetic factors, such as inherited gene mutations (e.g., BRCA1 and BRCA2) Hormonal influences, particularly estrogen exposure Lifestyle factors including alcohol consumption and obesity Previous history of breast abnormalities or early signs of breast cancer Environmental exposures that may impact breast tissue health
Key Symptoms: Often asymptomatic; discovered through screening mammograms Presence of calcifications detected on mammography Possible lump or thickening in the breast area Nipple changes, such as inversion or discharge (less common)
Diagnostic & Treatment
Diagnosis Path: Mammography: Most commonly used to identify abnormal calcifications indicative of DCIS Ultrasound: Assists in evaluating any palpable lumps and guiding biopsy procedures Biopsy procedures (such as stereotactic, wire-guided, or surgical biopsy): Confirm the presence of abnormal cells and determine the extent of the lesion Magnetic Resonance Imaging (MRI): May be employed for comprehensive evaluation if needed
Treatment Protocols: Surgical excision (lumpectomy): Removal of the DCIS with clear margins to preserve breast tissue Mastectomy: Complete removal of the affected breast, especially if the lesion is widespread or close to the skin Radiation therapy: Often recommended after lumpectomy to target residual abnormal cells Hormone therapy: Use of agents like tamoxifen or aromatase inhibitors for hormone receptor-positive DCIS to lower recurrence risk Active surveillance: Monitoring without immediate treatment in select low-risk cases, though this approach is less common
Clinical Advice & FAQs
Billing Guidance
Is D05.12 a billable ICD-10 code?
Yes, D05.12 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report D05.12?
Clinical documentation must specify the nature of Intraductal carcinoma in situ of left breast and any associated comorbidities for accurate reporting.
Cite this Clinical Reference